Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (Massachusetts General Hospital, bf8fc0)
- Development stage
- Unknown
- Lead developer
- Massachusetts General Hospital
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Cell Therapies
- Administration
- Oral
01
Overview
Fecal microbiota transplant (FMT) is an investigational live biotherapeutic product being studied at Massachusetts General Hospital for the treatment of high-risk acute graft-versus-host disease (GVHD) in patients who have undergone allogeneic hematopoietic cell transplantation. The intervention involves the administration of live microorganisms from the stool of healthy donors to restore intestinal microbiome diversity. Disruption of the gut microbiome is associated with the development and severity of acute GVHD. By replenishing beneficial commensal bacteria, FMT aims to modulate the recipient's immune response and improve clinical outcomes. Researchers at Massachusetts General Hospital have conducted Phase 1 and Phase 2 clinical trials evaluating the feasibility and efficacy of third-party donor FMT, administered as oral capsules, for both treatment-naïve and steroid-refractory acute GVHD.
- Other names
- FMTfecal microbiota transplantation
Beyond the preview
Go deeper on fecal microbiota transplant (Massachusetts General Hospital, bf8fc0).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (Massachusetts General Hospital, bf8fc0).